Livin serves as a prognostic marker for mid‑distal rectal cancer and a target of mid‑distal rectal cancer treatment

Su,Qi‑Biao; Wang,Lai‑You; Wei,Gui‑Ning; Liao,Li‑Zhen; Zhao,Jie; Liu,Hong‑Jun; Shi,Yu‑Long; Li,Le‑Ping; Li,Chen‑Sheng

doi:10.3892/ol.2017.7230

Livin serves as a prognostic marker for mid‑distal rectal cancer and a target of mid‑distal rectal cancer treatment

Authors:
- Qi‑Biao Su
- Lai‑You Wang
- Gui‑Ning Wei
- Li‑Zhen Liao
- Jie Zhao
- Hong‑Jun Liu
- Yu‑Long Shi
- Le‑Ping Li
- Chen‑Sheng Li
View Affiliations

Affiliations: College of Health Science, Guangdong Pharmaceutical University, Guangzhou, Guangdong 510006, P.R. China, College of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, Guangdong 510006, P.R. China, Department of Pharmacology, Guangxi Institute of Chinese Medicine and Pharmaceutical Science, Nanning, Guangxi 530022, P.R. China, Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China
Published online on: October 20, 2017 https://doi.org/10.3892/ol.2017.7230
Pages: 7759-7766
Copyright: © Su et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Livin is a novel member of the inhibitor of apoptosis protein family, which has been identified to be expressed in various malignancies and is suggested to be associated with poor prognostic significance. However, no data are available concerning the significance of livin in mid‑distal rectal cancer. In the present study, livin expression, and its association with clinicopathological characteristics and prognosis was examined in patients with mid‑distal rectal cancer. Apoptotic susceptibility, invasion capacity and chemosensitivity of LoVo cells were investigated using small interfering RNA (siRNA)‑mediated knockdown of livin. It was revealed that livin was highly expressed in mid‑distal rectal cancer tissues compared with the normal rectal mucosal tissues. Livin expression was associated with pathological grade, extent of invasion (T stage) and extent of lymph node metastasis (N stage) of tumor, contributing to poor prognosis of mid‑distal rectal cancer following surgery. The data suggest that aggressive surgery should be applied in patients with mid‑distal rectal cancer with high expression of livin. It was also revealed that knockdown of livin by siRNA increased the apoptotic rate, suppressed invasion of LoVo cells, and decreased the half‑maximal inhibitory concentration of oxaliplatin and 5‑fluorouracil by ~50% in LoVo cells significantly compared with control groups. The data suggested that a combination of downregulation of livin and anticancer drugs may significantly decrease the toxicity of anticancer drugs. Taken together, the present study indicated that livin may be a promising target in clinical therapy of mid‑distal rectal cancer.

View Figures

View References

1	GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. IARC; Lyon: 2015, http://globocan.iarc.fr/Default.aspxDecember 9–2015
2	Holmes D: A disease of growth. Nature. 521:S2–S3. 2015. View Article : Google Scholar : PubMed/NCBI
3	Phipps AI, Limburg PJ, Baron JA, Burnett-Hartman AN, Weisenberger DJ, Laird PW, Sinicrope FA, Rosty C, Buchanan DD, Potter JD, et al: Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 148(77–87): e22015.
4	Breugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L, Glynne-Jones R, Counsell N, Bastiaannet E, van den Broek CB, et al: Adjuvant chemotherapy after preoperative (chemo) radiotherapy and surgery for patients with rectal cancer: A systematic review and meta-analysis of individual patient data. Lancet Oncol. 16:200–207. 2015. View Article : Google Scholar : PubMed/NCBI
5	Janzen DM, Tiourin E, Salehi JA, Paik DY, Lu J, Pellegrini M and Memarzadeh S: Corrigendum: An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer. Nat Commun. 7:107032016. View Article : Google Scholar : PubMed/NCBI
6	Mullard A: Pioneering apoptosis-targeted cancer drug poised for FDA approval. Nat Rev Drug Discov. 15:147–149. 2016. View Article : Google Scholar : PubMed/NCBI
7	Bai L and Wang S: Targeting apoptosis pathways for new cancer therapeutics. Annu Rev Med. 65:139–155. 2014. View Article : Google Scholar : PubMed/NCBI
8	Fernald K and Kurokawa M: Evading apoptosis in cancer. Trends Cell Biol. 23:620–633. 2013. View Article : Google Scholar : PubMed/NCBI
9	Gyrd-Hansen M and Meier P: IAPs: From caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer. 10:561–574. 2010. View Article : Google Scholar : PubMed/NCBI
10	Wang S, Bai L, Lu J, Liu L, Yang CY and Sun H: Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeutics. J Mammary Gland Biol Neoplasia. 17:217–228. 2012. View Article : Google Scholar : PubMed/NCBI
11	Nachmias B, Ashhab Y and Ben-Yehuda D: The inhibitor of apoptosis protein family (IAPs): An emerging therapeutic target in cancer. Semin Cancer Biol. 14:231–243. 2004. View Article : Google Scholar : PubMed/NCBI
12	Chung CY, Park YL, Kim N, Park HC, Park HB, Myung DS, Kim JS, Cho SB, Lee WS and Joo YE: Expression and prognostic significance of Livin in gastric cancer. Oncol Rep. 30:2520–2528. 2013. View Article : Google Scholar : PubMed/NCBI
13	Ibrahim L, Aladle D, Mansour A, Hammad A, Al Wakeel AA and Abd El-Hameed SA: Expression and prognostic significance of livin/BIRC7 in childhood acute lymphoblastic leukemia. Med Oncol. 31:9412014. View Article : Google Scholar : PubMed/NCBI
14	Li F, Yin X, Luo X, Li HY, Su X, Wang XY, Chen L, Zheng K and Ren GS: Livin promotes progression of breast cancer through induction of epithelial-mesenchymal transition and activation of AKT signaling. Cell Signal. 25:1413–1422. 2013. View Article : Google Scholar : PubMed/NCBI
15	Lin X, Li HR, Lin XF, Yu ME, Tu XW, Hua ZD, Lin M, Xu NL, Han LL and Chen YS: Silencing of Livin inhibits tumorigenesis and metastasis via VEGF and MMPs pathway in lung cancer. Int J Oncol. 47:657–667. 2015.PubMed/NCBI
16	Xi RC, Sheng YR, Chen WH, Sheng L, Gang JJ, Tong Z, Shan Z, Ying GH and Dong LC: Expression of survivin and livin predicts early recurrence in non-muscle invasive bladder cancer. J Surg Oncol. 107:550–554. 2013. View Article : Google Scholar : PubMed/NCBI
17	Myung DS, Park YL, Chung CY, Park HC, Kim JS, Cho SB, Lee WS, Lee KH, Lee JH and Joo YE: Expression of Livin in colorectal cancer and its relationship to tumor cell behavior and prognosis. PLoS One. 8:e732622013. View Article : Google Scholar : PubMed/NCBI
18	Xi RC, Biao WS and Gang ZZ: Significant elevation of survivin and livin expression in human colorectal cancer: Inverse correlation between expression and overall survival. Onkologie. 34:428–432. 2011. View Article : Google Scholar : PubMed/NCBI
19	Associatioon TCoCCoCa-c: Guidelines for surgery of mid and distal rectal cancer. Chin J Gastrointest Surg. 10:1–7. 2007.
20	Bosman FT, Carneiro F, Hruban RH and Theise ND: WHO Classification of Tumours of the Digestive System. Fourth Edition. IARC Press; Lyon: 2010
21	International Union against Cancer: TNM classification of malignant tumours. Sobin LH, Gospodarowicz MK and Wittekind C: Wiley-Blackwell; Chichester, West Sussex, UK; Hoboken, NJ, USA: 2010
22	Yuan B, Ran B, Wang S, Liu Z, Zheng Z and Chen H: siRNA directed against Livin inhibits tumor growth and induces apoptosis in human glioma cells. J Neurooncol. 107:81–87. 2012. View Article : Google Scholar : PubMed/NCBI
23	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
24	Stewart CJ, Hillery S, Platell C and Puppa G: Assessment of serosal invasion and criteria for the classification of pathological (p) T4 staging in colorectal carcinoma: Confusions, controversies and criticisms. Cancers (Basel). 3:164–181. 2011. View Article : Google Scholar : PubMed/NCBI
25	Wang H, Wei XZ, Fu CG, Zhao RH and Cao FA: Patterns of lymph node metastasis are different in colon and rectal carcinomas. World J Gastroenterol. 16:5375–5379. 2010. View Article : Google Scholar : PubMed/NCBI
26	Saito N, Koda K, Takiguchi N, Oda K, Ono M, Sugito M, Kawashima K and Ito M: Curative surgery for local pelvic recurrence of rectal cancer. Dig Surg. 20:192–199; discussion 200. 2003. View Article : Google Scholar : PubMed/NCBI
27	Hellinger MD and Santiago CA: Reoperation for recurrent colorectal cancer. Clin Colon Rectal Surg. 19:228–236. 2006. View Article : Google Scholar : PubMed/NCBI
28	Pereira P, Ghouti L and Blanche J: Surgical treatment of extraluminal pelvic recurrence from rectal cancer: Oncological management and resection techniques. J Visc Surg. 150:97–107. 2013. View Article : Google Scholar : PubMed/NCBI
29	Byun DS, Cho K, Ryu BK, Lee MG, Kang MJ, Kim HR and Chi SG: Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res. 63:7068–7075. 2003.PubMed/NCBI
30	Cao J, Chen XP, Li WL, Xia J, Du H, Tang WB, Wang H, Chen XW, Xiao HQ and Li YY: Decreased fragile histidine triad expression in colorectal cancer and its association with apoptosis inhibition. World J Gastroenterol. 13:1018–1026. 2007. View Article : Google Scholar : PubMed/NCBI
31	Mesri M, Wall NR, Li J, Kim RW and Altieri DC: Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest. 108:981–990. 2001. View Article : Google Scholar : PubMed/NCBI
32	Kanemitsu Y, Kato T, Hirai T, Yasui K, Morimoto T, Shimizu Y, Kodera Y and Yamamura Y: Survival after curative resection for mucinous adenocarcinoma of the colorectum. Dis Colon Rectum. 46:160–167. 2003. View Article : Google Scholar : PubMed/NCBI
33	Sternberg A, Sibirsky O, Cohen D, Blumenson LE and Petrelli NJ: Validation of a new classification system for curatively resected colorectal adenocarcinoma. Cancer. 86:782–792. 1999. View Article : Google Scholar : PubMed/NCBI
34	Tsai HL, Lu CY, Hsieh JS, Wu DC, Jan CM, Chai CY, Chu KS, Chan HM and Wang JY: The prognostic significance of total lymph node harvest in patients with T2-4N0M0 colorectal cancer. J Gastrointest Surg. 11:660–665. 2007. View Article : Google Scholar : PubMed/NCBI
35	Holm T, Ljung A, Haggmark T, Jurell G and Lagergren J: Extended abdominoperineal resection with gluteus maximus flap reconstruction of the pelvic floor for rectal cancer. Br J Surg. 94:232–238. 2007. View Article : Google Scholar : PubMed/NCBI
36	Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet. 375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI